How to Treat Elevated Erythrocyte Sedimentation Rate (ESR) in Rheumatoid Arthritis
Jun 09, 2022
Source: Cainiu Health
Dr. Liu Aihua
Introduction
Patients with rheumatoid arthritis and elevated erythrocyte sedimentation rate (ESR) typically require anti-inflammatory and analgesic therapy, immunosuppressive therapy, and biologic agent therapy. Initial treatment generally involves anti-inflammatory and analgesic medications—most commonly nonsteroidal anti-inflammatory drugs (NSAIDs). If the inflammatory marker ESR is markedly elevated, low-dose glucocorticoids should be considered. Immunosuppressive therapy is also an option.
Rheumatoid arthritis (RA) is generally a chronic, systemic inflammatory disease of unknown etiology, characterized by polyarticular, symmetric, and erosive arthritis primarily affecting the small joints of the hands and feet. It is frequently accompanied by extra-articular manifestations and seropositivity for rheumatoid factor (RF), potentially leading to joint deformities and functional impairment. So, how is elevated erythrocyte sedimentation rate (ESR) managed in RA?
How to Treat Elevated ESR in Rheumatoid Arthritis
Patients with RA and elevated ESR typically require anti-inflammatory and analgesic therapy, immunosuppressive therapy, and biologic agent therapy. Initial treatment usually involves nonsteroidal anti-inflammatory drugs (NSAIDs) for inflammation control and pain relief. If the inflammatory marker ESR remains significantly elevated, low-dose glucocorticoids may be considered. Immunosuppressive agents may also be prescribed. If NSAIDs and immunosuppressants prove insufficient, biologic agents—under physician guidance—should be considered. Additionally, disease-modifying antirheumatic drugs (DMARDs) should be used concurrently to improve disease control, thereby slowing and halting disease progression. Biologic agents may also be employed when necessary.
An elevated ESR in RA patients often indicates active disease—possibly due to delayed initiation of therapy or inadequate disease control with current medications. Without timely intervention, patients may develop joint swelling and pain, progressing over time to irreversible joint deformities. Infections—including respiratory, gastrointestinal, and urogenital infections—can also elevate ESR. Furthermore, physiological fluctuations in ESR may occur during menstruation in women. Therefore, when interpreting ESR as a marker of disease activity, other potential causes of ESR elevation must first be ruled out.
With appropriate treatment over time, inflammatory markers such as ESR typically decrease. We hope this information is helpful to you.
